📣 VC round data is live. Check it out!

Artivion Valuation Multiples

Discover Artivion's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like ChemoMetec, MedicalSystem Technology, Conmed, SEEGENE and more.

Artivion Overview

About Artivion

Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.


Founded

1984

HQ

United States

Employees

1.8K

Financials (LTM)

Revenue: $460M
EBITDA: $93M

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Artivion Financials

Artivion reported last 12-month revenue of $460M and EBITDA of $93M.

In the same LTM period, Artivion generated $298M in gross profit, $93M in EBITDA, and $8M in net income.

Revenue (LTM)


Artivion P&L

In the most recent fiscal year, Artivion reported revenue of $441M and EBITDA of $90M.

Artivion is profitable as of last fiscal year, with gross margin of 64%, EBITDA margin of 20%, and net margin of 2%.

See analyst estimates for Artivion
LTMLast FY202320242025202620272028
Revenue$460M$441M$354M$389M$441M
Gross Profit$298M$284M$229M$249M$284M
Gross Margin65%64%65%64%64%
EBITDA$93M$90M$27M$51M$64M
EBITDA Margin20%20%8%13%14%
EBIT Margin7%8%(2%)10%6%
Net Profit$8M$10M($31M)($13M)$10M
Net Margin2%2%(9%)(3%)2%
Net Debt-$150M---

Financial data powered by Morningstar, Inc.

Artivion Stock Performance

Artivion has current market cap of $991M, and enterprise value of $1B.

Market Cap Evolution


Artivion's stock price is $20.42.

Artivion share price decreased by 8.0% in the last 30 days, and by 34.3% in the last year.

Artivion has an EPS (earnings per share) of $0.20.

See more trading valuation data for Artivion
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$991M-3.0%-8.0%-44.2%-34.3%$0.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Artivion Valuation Multiples

Artivion trades at 2.6x EV/Revenue multiple, and 12.9x EV/EBITDA.

See NTM and 2027E valuation multiples for Artivion

EV / Revenue (LTM)


Artivion Financial Valuation Multiples

As of June 3, 2026, Artivion has market cap of $991M and EV of $1B.

Artivion has a P/E ratio of 120.3x.

LTMLast FY202320242025202620272028
EV/Revenue2.6x2.7x3.4x3.1x2.7x
EV/EBITDA12.9x13.3x44.6x23.4x18.7x
EV/EBIT35.4x35.4x(140.3x)30.7x44.6x
EV/Gross Profit4.0x4.2x5.2x4.8x4.2x
P/E120.3x101.5x(32.3x)(74.2x)101.5x
EV/FCF(154.6x)n/m104.8x108.0xn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Artivion Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Artivion Margins & Growth Rates

Artivion grew revenue by 10% and EBITDA by 8% in the last fiscal year.

In the most recent fiscal year, Artivion reported gross margin of 64%, EBITDA margin of 20%, and net margin of 2%.

See estimated margins and future growth rates for Artivion

Artivion Margins

Last FY202420252026202720282029
Gross Margin64%64%64%65%
EBITDA Margin20%13%14%20%
EBIT Margin8%10%6%7%
Net Margin2%(3%)2%1%
FCF Margin0%3%0%(4%)

Artivion Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth10%10%14%10%
Gross Profit Growth11%9%14%11%
EBITDA Growth8%90%25%51%
EBIT Growth0%(557%)(31%)26%
Net Profit Growth(37%)(56%)(173%)(37%)
FCF Growth(2412%)(3%)(92%)(2412%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Artivion Operational KPIs

Artivion's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Artivion's Rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Artivion's Rule of X is 45% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Artivion
LTMLast FY202320242025202620272028
Rule of 4031%30%---
Bessemer Rule of X47%45%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
G&A Expenses to Revenue50%51%--51%
R&D Expenses to Revenue7%7%8%7%7%
Opex to Revenue-58%67%54%58%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Artivion Competitors

Artivion competitors include ChemoMetec, MedicalSystem Technology, Conmed, SEEGENE, Kuros Biosciences, Shanghai Haohai, Xvivo Perfusion, Mani Inc., Curiox Biosystems and Dynavox Group.

Most Artivion public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
ChemoMetec12.2x11.9x23.3x21.7x
MedicalSystem Technology21.4x19.2x72.6x83.5x
Conmed1.3x1.3x6.7x6.7x
SEEGENE1.9x1.9x7.4x7.7x
Kuros Biosciences5.0x5.4x57.6x46.4x
Shanghai Haohai2.0x2.0x10.7x9.6x
Xvivo Perfusion10.0x9.3x50.4x43.9x
Mani Inc.4.6x4.4x13.0x12.2x

This data is available for Pro users. Sign up to see all Artivion competitors and their valuation data.

Start Free Trial

Acquisitions by Artivion

Artivion has acquired 4 companies to date.

Last acquisition by Artivion was on May 17th 2026. Artivion acquired EndoSpan for $175M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Artivion

EndoSpan
Ascyrus Medical
JOTEC
On-X Life Technologies
Description
EndoSpan is a medical device company headquartered in Herzliya, Israel. It develops the Meridian endovascular graft for abdominal aortic aneurysm repair, featuring a single-branch proximal design for juxtarenal anatomies. The system received CE Mark in 2020 after European trials showing high sealing rates. EndoSpan's platform accommodates off-the-shelf deployment in challenging necks.
-
JOTEC is a Hechingen-headquartered developer of endovascular devices for aortic and peripheral vascular treatments. The German firm produces stents, grafts, and implants for cardiac surgery, radiology, and interventional procedures. JOTEC's portfolio includes fenestrated and branched stent grafts acquired by Artiomed in recent years, with distribution across Europe and beyond.
On-X Life Technologies is an Austin-based medical device company manufacturing mechanical heart valves and repair products. Its portfolio includes aortic and mitral valves with Conform-X sewing rings, plus ascending aortic prostheses approved by FDA and CE Mark. Used in over 100,000 implants worldwide, the valves feature pure pyrolytic carbon leaflets for durability up to 20 years. Incorporated in 1994, On-X supplies hospitals in the U.S. and Europe.
HQ CountryIsraelUnited StatesGermanyUnited States
HQ City
Herzliya
-
Hechingen
Austin, TX
Deal Date17 May 20262 Sep 20204 Dec 201720 Dec 2015
Valuation$175M$200M$225M$130M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Artivion acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Artivion

Artivion has invested in 1 company to date.

Latest investment by Artivion was on September 12th 2019. Artivion invested in EndoSpan in their $10M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Artivion

EndoSpan
Description
EndoSpan is a medical device company headquartered in Herzliya, Israel. It develops the Meridian endovascular graft for abdominal aortic aneurysm repair, featuring a single-branch proximal design for juxtarenal anatomies. The system received CE Mark in 2020 after European trials showing high sealing rates. EndoSpan's platform accommodates off-the-shelf deployment in challenging necks.
HQ CountryIsrael
HQ City
Herzliya
Deal Date12 Sep 2019
RoundSeries A
Raised$10M
InvestorsArtivion
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Artivion investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Artivion

When was Artivion founded?Artivion was founded in 1984.
Where is Artivion headquartered?Artivion is headquartered in United States.
How many employees does Artivion have?As of today, Artivion has over 1K employees.
Who is the CEO of Artivion?Artivion's CEO is James Patrick Mackin.
Is Artivion publicly listed?Yes, Artivion is a public company listed on NYSE.
What is the stock symbol of Artivion?Artivion trades under AORT ticker.
When did Artivion go public?Artivion went public in 1993.
Who are competitors of Artivion?Artivion main competitors include ChemoMetec, MedicalSystem Technology, Conmed, SEEGENE, Kuros Biosciences, Shanghai Haohai, Xvivo Perfusion, Mani Inc., Curiox Biosystems, Dynavox Group.
What is the current market cap of Artivion?Artivion's current market cap is $991M.
What is the current revenue of Artivion?Artivion's last 12 months revenue is $460M.
What is the current revenue growth of Artivion?Artivion revenue growth (NTM/LTM) is 11%.
What is the current EV/Revenue multiple of Artivion?Current revenue multiple of Artivion is 2.6x.
What is the current EBITDA of Artivion?Artivion's last 12 months EBITDA is $93M.
What is Artivion's EBITDA margin?Artivion's last 12 months EBITDA margin is 20%.
What is the current EV/EBITDA multiple of Artivion?Current EBITDA multiple of Artivion is 12.9x.
What is the current FCF of Artivion?Artivion's last 12 months FCF is ($8M).
What is Artivion's FCF margin?Artivion's last 12 months FCF margin is (2%).
What is the current EV/FCF multiple of Artivion?Current FCF multiple of Artivion is (154.6x).
How many companies Artivion has acquired to date?As of June 2026, Artivion has acquired 4 companies.
What was the largest acquisition by Artivion?$225M acquisition of JOTEC on 4th December 2017 was the largest M&A Artivion has done to date.
In how many companies Artivion has invested to date?As of June 2026, Artivion has invested in 1 company.
What was the last Artivion investment?On 12th September 2019 Artivion invested in EndoSpan, participating in a $10M Series A round.
In what companies Artivion invested in?Artivion invested in EndoSpan.

See public comps similar to Artivion

Lists including Artivion

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial